Peer review reports
From: Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Original Submission | ||
---|---|---|
1 Jul 2018 | Submitted | Original manuscript |
19 Jul 2018 | Author responded | Author comments - Moira Cuncannon |
Resubmission - Version 2 | ||
19 Jul 2018 | Submitted | Manuscript version 2 |
15 Aug 2018 | Reviewed | Reviewer Report - Gaetano Finocchiaro |
27 Aug 2018 | Reviewed | Reviewer Report - Quintino Giorgio D'Alessandris |
9 Oct 2018 | Author responded | Author comments - Moira Cuncannon |
Resubmission - Version 3 | ||
9 Oct 2018 | Submitted | Manuscript version 3 |
28 Oct 2018 | Reviewed | Reviewer Report - Quintino Giorgio D'Alessandris |
2 Nov 2018 | Reviewed | Reviewer Report - Gaetano Finocchiaro |
29 Nov 2018 | Author responded | Author comments - Moira Cuncannon |
Resubmission - Version 4 | ||
29 Nov 2018 | Submitted | Manuscript version 4 |
21 Dec 2018 | Reviewed | Reviewer Report - Reviewer 2 |
12 Mar 2019 | Author responded | Author comments - Moira Cuncannon |
Resubmission - Version 5 | ||
12 Mar 2019 | Submitted | Manuscript version 5 |
27 Mar 2019 | Reviewed | Reviewer Report - Reviewer 2 |
11 Apr 2019 | Reviewed | Reviewer Report - Maurizio MARTINI |
13 Apr 2019 | Author responded | Author comments - Moira Cuncannon |
Resubmission - Version 6 | ||
13 Apr 2019 | Submitted | Manuscript version 6 |
24 Apr 2019 | Author responded | Author comments - Moira Cuncannon |
Resubmission - Version 7 | ||
24 Apr 2019 | Submitted | Manuscript version 7 |
Publishing | ||
3 May 2019 | Editorially accepted | |
14 May 2019 | Article published | 10.1186/s12885-019-5678-1 |